Can I Take Resveratrol with Viagra? What the Evidence Says

Sildenafil citrate, marketed as Viagra, is an FDA-approved phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction. Resveratrol is not a drug; it is a dietary polyphenol supplement, distinct from prescription PDE5 inhibitors and not FDA-regulated for any drug indication. The question below is narrow: does taking resveratrol alongside sildenafil change how sildenafil behaves in the body, and is that change large enough to matter for an ordinary user.

The core answer

Sildenafil is cleared primarily by CYP3A4. Resveratrol has been shown in vitro to inhibit CYP3A4, which is pharmacologically plausible grounds for a drug interaction, but no controlled human study of sildenafil plus resveratrol has been published, so the real-world size of any exposure increase is not established. Separately, sildenafil lowers blood pressure on its own, and resveratrol has been studied for blood-pressure-lowering effects in some hypertensive populations, so an additive drop in blood pressure is the more concrete, verifiable risk of combining the two. Until direct trial data exist, the reasonable approach is dose separation, conservative sildenafil dosing, and blood-pressure monitoring, not avoidance by default.

Why CYP3A4 is the mechanism in question

Sildenafil undergoes substantial first-pass liver metabolism, and CYP3A4 is described in its FDA prescribing information as the major metabolic pathway, with a minor contribution from CYP2C9. The label documents that known CYP3A4 inhibitors change sildenafil exposure meaningfully: the strong inhibitor ritonavir and the moderate inhibitor erythromycin both increase sildenafil blood levels substantially when co-administered (per the FDA prescribing information). This establishes the general principle that CYP3A4 inhibition of any strength can raise sildenafil exposure. It does not establish where resveratrol sits on that spectrum, because resveratrol was not part of the studies that generated the label's interaction data.

Laboratory research using human liver enzyme preparations has reported that resveratrol inhibits CYP3A4 activity, and review articles describe it as a mild-to-moderate CYP3A4 inhibitor in vitro. Whether oral supplement doses produce concentrations at the liver and gut wall high enough to meaningfully replicate that laboratory effect in a living person is genuinely unsettled. Resveratrol also has poor oral bioavailability, much of it is converted to inactive conjugates before reaching systemic circulation, and this limits how much of an enzyme-inhibiting effect a typical capsule dose can produce. A precise percentage increase in sildenafil exposure from resveratrol cannot be responsibly stated because no human pharmacokinetic study of the pairing has been identified; any specific number attached to this claim should be treated as unverified until checked against the primary pharmacology literature.

Should you worry about blood pressure more than the enzyme interaction?

This is arguably the more actionable question. Sildenafil is well documented to produce a modest, dose-related reduction in blood pressure through nitric oxide and cyclic GMP signaling, and this effect is described in its FDA label as part of its known pharmacology, including the absolute contraindication with nitrate medications. Resveratrol has been studied in small randomized trials for blood-pressure effects, with some trials in hypertensive or overweight populations reporting reductions in systolic blood pressure at supplement-range doses. The exact magnitude reported varies across trials and populations, and a firm combined number for "how much blood pressure drop to expect" from stacking the two agents does not exist. What is reasonable to say is that two agents that each independently lower blood pressure, through different mechanisms, create a plausible additive effect that is worth monitoring rather than ignoring, particularly in anyone already on antihypertensive medication, an alpha-blocker, or a nitrate (nitrates are an absolute contraindication with sildenafil regardless of any supplement use).

An evidence-status interaction assessment

Before relying on any of the plausible-but-unproven rows above for a personal decision, verification against current primary literature and a conversation with a pharmacist or prescriber is the appropriate next step, especially if you take other antihypertensives, alpha-blockers, or additional CYP3A4-affecting medications or supplements.

Practical steps if you take both

Dose timing. Taking resveratrol with a morning meal and sildenafil later in the day creates more separation between resveratrol's peak effect and the moment sildenafil undergoes first-pass metabolism. If same-day timing isn't practical, a gap of several hours between the two is a reasonable, low-cost precaution, though no trial has established a specific "safe" separation interval for this pair.

Starting dose. If you already take resveratrol regularly and are newly prescribed sildenafil, discuss starting at the lowest effective sildenafil dose (25 mg) rather than a higher dose, so you and your prescriber can gauge the combined effect before increasing.

Blood pressure monitoring. Check blood pressure with a validated upper-arm cuff before starting the combination and again after taking sildenafil on a few separate occasions in the first weeks. A systolic reading below 90 mmHg, a drop of more than about 20 mmHg from your usual seated baseline, or symptoms such as lightheadedness on standing, prolonged headache, or visual changes are reasons to stop the supplement and contact your prescriber rather than waiting it out.

Absolute contraindication. Regardless of resveratrol use, sildenafil must never be combined with nitrate medications because of the risk of severe, potentially life-threatening hypotension. This is unrelated to resveratrol and applies to anyone on nitrate therapy.

Already combining both without issue? Tolerating the combination without symptoms for weeks or months is reassuring but does not permanently rule out an effect, particularly if either dose changes or a new medication is added. Periodic blood-pressure checks remain reasonable even after an initial stable period.

What is not established

No published human pharmacokinetic study measuring sildenafil levels with and without concurrent resveratrol was identified for this article. No case report of clinically significant harm from this specific combination was identified either. This means the interaction should be treated as biologically plausible and worth managing conservatively, not as a proven, quantified risk. Readers and clinicians should verify any precise numeric claims (exposure percentage changes, specific blood-pressure deltas from combining the two) against current primary pharmacology and clinical literature before treating them as settled facts.

When to seek urgent care

Chest pain, fainting, sudden vision loss, an erection lasting more than four hours, or a blood pressure reading well below your normal range accompanied by dizziness or confusion after taking sildenafil, with or without resveratrol, warrants urgent medical attention rather than home monitoring.